Presentations & Publications

Presentation

Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model

2018 Keystone Symposia on Cancer Immunotherapies: Combinations, March 25, 2018

Publication

Immunotherapy: A New Strategy for the Treatment of Cervical Cancer

Interview with Dr. Christian Marth and Dr. Sharad Ghamande

Publication

Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer

International Journal of Radiation Oncology, January 2018

Presentation

Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation

SITC, November 13, 2017

Presentation

Baseline serum protein levels associated with survival in axalimogene filolisbac (AXAL)-treated metastatic cervical cancer patients: The GOG/NRG-0265 trial

ESGO, November 2017

Presentation

Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model

CRI-CIMT-EATI-AACR, September 9, 2017

Publication

Therapeutic options for treatment of human papillomavirus-associated cancers – novel immunologic vaccines: ADXS11–001

Published in Gynecologic Oncology Research and Practice on July 14, 2017

Publication

Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy

Published in Immuno-Oncology News, June 29, 2017

Presentation

2017 Investor Analyst Day

June 12, 2017

Publication

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

Published in Gynecologic Oncology Research and Practice on June 2, 2017

Presentation

High-dose treatment with ADXS11-001, a Listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

SGO, March 27, 2017

Presentation

A prospective phase 2 trial (GOG-0265) of the Listeria-based HPV immunotherapy axalimogene filolisbac (AXAL) in second- and third- line metastatic cervical cancer: An NRG Oncology Group trial

SGO, March 13, 2017

Presentation

HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (#7632)

AACR, September 2016

Presentation

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

ASCO, June 6, 2016

Presentation

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

ASCO, June 6, 2016